BRCA2 and neoplasm: The separation from the non-BRCA1/BRCA2 tumours is mainly driven by homologue repair deficiency (HRD), i.e. the HRD-associated substitution signature (SBS) 3, where a higher level is detected in the BRCA1/BRCA2-mutated tumours.